References
1. Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform
hemangioendothelioma: Atypical features and risks of kasabach-merritt
phenomenon in 107 referrals. Journal of Pediatrics .
2013;162(1):142-147. doi:10.1016/j.jpeds.2012.06.044
2. Mahajan P, Margolin J, Iacobas I. Kasabach-Merritt Phenomenon:
Classic Presentation and Management Options. Clinical Medicine
Insights: Blood Disorders . 2017;10:0-4. doi:10.1177/1179545X17699849
3. Chinello M, Di Carlo D, Olivieri F, et al. Successful management of
kaposiform hemangioendothelioma with long-term sirolimus treatment: A
case report and review of the literature. Mediterranean Journal of
Hematology and Infectious Diseases . 2018;10(1):1-6.
doi:10.4084/MJHID.2018.043
4. Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt
syndrome do not have “true” hemangiomas. Journal of Pediatrics .
1997;130(4):631-640. doi:10.1016/S0022-3476(97)70249-X
5. Kasabach H, Merritt K. Capillary Hemangioma With Extensive Purpura.American Journal of Diseases of Children . 1940;59(5):1063-1070.
doi:10.1001/archpedi.1940.01990160135009
6. O’Rafferty C, O’Regan GM, Irvine AD, Smith OP. Recent advances in the
pathobiology and management of Kasabach-Merritt phenomenon.British Journal of Haematology . 2015;171(1):38-51.
doi:10.1111/bjh.13557
7. Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform Hemangioendothelioma
of Infancy and Childhood. The American Journal of Surgical
Pathology . 1993;17(4):321-328. doi:10.1097/00000478-199304000-00001
8. Debelenko L V., Perez-Atayde AR, Mulliken JB, Liang MG, Archibald TH,
Kozakewich HPW. D2-40 immunohistochemical analysis of pediatric vascular
tumors reveals positivity in kaposiform hemangioendothelioma.Modern Pathology . 2005;18(11):1454-1460.
doi:10.1038/modpathol.3800444
9. Seo SK, Suh JC, Na GY, Kim IS, Sohn KR. Kasabach-Merritt syndrome:
Identification of platelet trapping in a tufted angioma by
immunohistochemistry technique using monoclonal antibody to CD61.Pediatric Dermatology . 1999;16(5):392-394.
doi:10.1046/j.1525-1470.1999.00103.x
10. Yao W, Li KL, Qin ZP, et al. Standards of care for Kasabach−Merritt
phenomenon in China. World Journal of Pediatrics .
2021;17(2):123-130. doi:10.1007/s12519-020-00379-9
11. Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor
CLEC-2: From discovery to prospects. Journal of Thrombosis and
Haemostasis . 2011;9(1):44-55. doi:10.1111/j.1538-7836.2011.04335.x
12. Bertozzi CC, Schmaier AA, Mericko P, et al. Platelets regulate
lymphatic vascular development through CLEC-2-SLP-76 signaling.Blood . 2010;116(4):661-670. doi:10.1182/blood-2010-02-270876
13. Gros A, Syvannarath V, Lamrani L, et al. Single platelets seal
neutrophil-induced vascular breaches via GPVI during
immune-complex-mediated inflammation in mice. Blood .
2015;126(8):1017-1026. doi:10.1182/blood-2014-12-617159
14. Rayes J, Lax S, Wichaiyo S, et al. The podoplanin-CLEC-2 axis
inhibits inflammation in sepsis. Nature Communications .
2017;8(1). doi:10.1038/s41467-017-02402-6
15. Payne H, Ponomaryov T, Watson SP, Brill A. Mice with a deficiency in
CLEC-2 are protected against deep vein thrombosis. Blood .
2017;129(14):2013-2020. doi:10.1182/blood-2016-09-742999
16. Inoue O, Hokamura K, Shirai T, et al. Vascular smooth muscle cells
stimulate platelets and facilitate thrombus formation through platelet
CLEC-2: Implications in atherothrombosis. PLoS ONE .
2015;10(9):1-28. doi:10.1371/journal.pone.0139357
17. Klement GL, Yip TT, Cassiola F, et al. Platelets actively sequester
angiogenesis regulators. Blood . 2009;113(12):2835-2842.
doi:10.1182/blood-2008-06-159541
18. Phillips WG, Marsden JR. Kasabach-Merritt syndrome exacerbated by
platelet transfusion. Journal of the Royal Society of Medicine .
1993;86(4):231-232. doi:10.1177/014107689308600418
19. Drolet BA, Trenor CC, Brandão LR, et al. Consensus-derived practice
standards plan for complicated kaposiform hemangioendothelioma.Journal of Pediatrics . 2013;163(1):285-291.
doi:10.1016/j.jpeds.2013.03.080
20. Koerper MA, Addiego JE, de Lorimier AA, Lipow H, Price D, Lubin BH.
Use of aspirin and dipyridamole in children with platelet trapping
syndromes. Journal of Pediatrics . 1983;102:311-314.
21. McCarthy CP, Steg G, Bhatt DL. The management of antiplatelet
therapy in acute coronary syndrome patients with thrombocytopenia: a
clinical conundrum. European Heart Journal .
2017;38(47):3488-3492. doi:10.1093/eurheartj/ehx531
22. Thachil J. Antiplatelet therapy – a summary for the general
physicians. Clin Med . 2016;16(2):152-160.
doi:10.7861/clinmedicine.16-2-152
23. Eble JA, Beermann B, Hinz HJ, Schmidt-Hederich A. α2β1 Integrin Is
Not Recognized by Rhodocytin but Is the Specific, High Affinity Target
of Rhodocetin, an RGD-independent Disintegrin and Potent Inhibitor of
Cell Adhesion to Collagen. Journal of Biological Chemistry .
2001;276(15):12274-12284. doi:10.1074/jbc.M009338200
24. Suzuki-Inoue K. A novel Syk-dependent mechanism of platelet
activation by the C-type lectin receptor CLEC-2. Blood .
2006;107(2):542-549. doi:10.1182/blood-2005-05-1994
25. Chang YW, Hsieh PW, Chang YT, et al. Identification of a novel
platelet antagonist that binds to CLEC-2 and suppresses
podoplanin-induced platelet aggregation and cancer metastasis.Oncotarget . 2015;6(40):42733-42748. doi:10.18632/oncotarget.5811
26. Ignatova AA, Ponomarenko EA, Polokhov DM, et al. Flow cytometry for
pediatric platelets. Platelets . 2019;30(4):428-437.
doi:10.1080/09537104.2018.1513473
27. Martyanov AA, Morozova DS, Sorokina MA, et al. Heterogeneity of
integrin αIIbβ3 function in pediatric immune thrombocytopenia revealed
by continuous flow cytometry analysis. International Journal of
Molecular Sciences . 2020;21(9). doi:10.3390/ijms21093035
28. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+
indicators with greatly improved fluorescence properties. Journal
of Biological Chemistry . 1985;260(6):3440-3450.
doi:10.1016/s0021-9258(19)83641-4
29. Mindukshev I, Gambaryan S, Kehrer L, et al. Low angle light
scattering analysis: A novel quantitative method for functional
characterization of human and murine platelet receptors. Clinical
Chemistry and Laboratory Medicine . 2012;50(7):1253-1262.
doi:10.1515/CCLM.2011.817
30. Greinacher A, Pecci A, Kunishima S, et al. Diagnosis of inherited
platelet disorders on a blood smear: a tool to facilitate worldwide
diagnosis of platelet disorders. Journal of Thrombosis and
Haemostasis . 2017;15(7):1511-1521. doi:10.1111/jth.13729
31. Morozova DS, Martyanov AA, Korobkina JJD, et al. Granulocytes role
in thrombus formation under low shear rate flow conditions as
procoagulant platelet scavengers. Published online 2020.
32. Gracheva MA, Urnova ES, Sinauridze EI, et al. Thromboelastography,
thrombin generation test and thrombodynamics reveal hypercoagulability
in patients with multiple myeloma. Leukemia and Lymphoma .
2015;56(12):3418-3425. doi:10.3109/10428194.2015.1041385
33. Mack JM, Verkamp B, Richter GT, Nicholas R, Stewart K, Crary SE.
Effect of sirolimus on coagulopathy of slow-flow vascular malformations.Pediatr Blood Cancer . 2019;66(10):e27896. doi:10.1002/pbc.27896
34. Martyanov AA, Balabin FA, Dunster JL, Panteleev MA, Gibbins JM,
Sveshnikova AN. Control of Platelet CLEC-2-Mediated Activation by
Receptor Clustering and Tyrosine Kinase Signaling. Biophysical
Journal . Published online April 2020:S0006349520303465.
doi:10.1016/j.bpj.2020.04.023
35. Sveshnikova A. Hubs and Webs in Platelet Intracellular Signalling.SBPR . 2021;1(3):31-32. doi:10.52455/sbpr.01.202103014
36. Sveshnikova A, Stepanyan M, Panteleev M, Sveshnikova A, Stepanyan M,
Panteleev M. Platelet functional responses and signalling: the molecular
relationship. Part 1: responses. Systems Biology and Physiology
Reports . 2021;1(1):20. doi:10.52455/sbpr.01.202101014
37. Folpe AL, Veikkola T, Valtola R, Weiss SW. Vascular endothelial
growth factor receptor-3 (VEGFR-3): A marker of vascular tumors with
presumed lymphatic differentiation, including Kaposi’s sarcoma,
kaposiform and Dabska-type hemangioendotheliomas, and a subset of
angiosarcomas. Modern Pathology . 2000;13(2):180-185.
doi:10.1038/modpathol.3880033